Last updated on February 2018

A Phase 3 Trial of the Safety Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Brief description of study

A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a 2:1 ratio (TransCon hGH : Genotropin). This is a global trial that will be conducted in, but not limited to, the United States, Canada, Germany, France, Poland, Bulgaria, Russia and Australia.

Clinical Study Identifier: NCT02781727

Contact Investigators or Research Sites near you

Start Over

Michael Beckert, MD

Rocky Mountain Pediatric Endocrinology
Centennial, CO United States